Overview
Information & Communication

SUSMED,Inc.

SUSMED, Inc. is a Japanese digital therapeutics (DTx) company focused on developing software-based medical treatments, including a regulatory-approved therapeutic app for insomnia disorder (approved by Japan's MHLW in February 2023, with a partial change approval in September 2025). The company operates two segments: the DTx Product Business, which develops and commercializes therapeutic apps across disease areas, and the DTx Platform Business, which provides a proprietary clinical trial management system and machine learning-based automated medical data analysis tools to pharmaceutical companies, academic institutions, CROs, and medical institutions. SUSMED's competitive strengths lie in its integrated ICT-driven approach to reducing clinical development costs and timelines, while enabling remote clinical trials and real-world data utilization.

Market Cap
¥5.85B
US$37.3M
EV
¥2.15B
US$13.7M
Stock¥347▼-1.98%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
1.5
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-82.9%pt
10012
Oct 24, 25 – Oct 23, 26StockTOPIX
1Mar 10, 26Strong rebound on positive quarterly earnings
2Aug 10, 26FY6/26 net loss ¥382M widens; FY6/27 guidance loss ¥541M
MC → EV Bridge
5.85BUS$37.3MMarket Cap0.00BUS$0.00M+ Debt3.70BUS$23.6M− Cash0.00BUS$0.00M− Inv. Sec.2.15BUS$13.7MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.32US$2.02M'22/60.53US$3.38M'23/60.34US$2.18M'24/60.46US$2.95M'25/60.50US$3.17M'26/6
EBITDA 5Y (¥B)
-0.23-US$1.45M'22/6-0.04-US$0.27M'23/6-0.36-US$2.28M'24/6-0.29-US$1.86M'25/6-0.32-US$2.04M'26/6
Net Income 5Y (¥B)
-0.23-US$1.49M'22/6-0.05-US$0.32M'23/6-0.36-US$2.28M'24/6-0.30-US$1.90M'25/6-0.38-US$2.44M'26/6
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
4.90US$31.3M'22/65.05US$32.2M'23/64.85US$30.9M'24/64.40US$28.0M'25/63.70US$23.6M'26/6
Shareholders
Top 10 hold 70.2%
1
Taro UENO
41.30%
2
Custody Bank of Japan, Ltd. (Trust Account)
7.40%
3
Healthia Co., Ltd.
4.70%
4
SUZUKEN CO.,LTD.
4.10%
5
The Dai-ichi Life Insurance Company, Limited
3.40%
6
BBH CO FOR ARCUS JAPAN VALUE FUND (Standing Proxy: MUFG Bank, Ltd.)
2.20%
7
Mitsubishi UFJ eSmart Securities Co., Ltd.
2.10%
8
JP JPMSE LUX RE UBS AG LONDON BRANCH EQ CO (Standing Proxy: MUFG Bank, Ltd.)
1.90%
9
MSIP CLIENT SECURITIES (Standing Proxy: Morgan Stanley MUFG Securities Co., Ltd.)
1.70%
10
SAWAI GROUP HOLDINGS Co.,Ltd.
1.40%
Management
7 officers
Taro UENO
Representative Director, President
Apr 2006 Resident Physician, Tokyo Metropolitan Hiroo Hospital Apr 2009 Research Fellow (DC1), Japan Society for the Promotion of Science Mar 2012 Completed Doctoral Program, Graduate School of Medical Sciences, Kumamoto University Apr 2013 Research Fellow (PD), Japan Society for the Promotion of Science Oct 2014 Physician, Seiwa Hospital affiliated with The Neurological Institute (Public Interest Foundation) (current) Apr 2015 Chief Researcher, Tokyo Metropolitan Institute of Medical Science (Public Interest Foundation) Jul 2015 Founder, Representative Member, SasMed LLC Feb 2016 Established SasMed Inc.; Representative Director, President (current) Apr 2016 Lecturer, Toho University Feb 2021 Outside Director, XNef Inc. Sep 2024 Director, National Council of Medical School-Originated Ventures (General Incorporated Association) (current)
1980-12-21
Takayuki OHARA
Director
Apr 2001 Joined Funai Soken Inc. Jan 2006 Joined Daiwa SMBC Securities Co., Ltd. (now Daiwa Securities Co., Ltd.) Dec 2007 Passed U.S. CPA Examination (Inactive) Jul 2013 Completed MBA, London Business School Mar 2015 Joined i-Style Co., Ltd.; seconded to Cosmenext Co., Ltd. (now i-Style Retail Co., Ltd.) Jul 2015 Director, Cosmenext Co., Ltd. Sep 2018 Outside Director, Touchcard Inc. May 2019 Representative Director, Yasumasu Co., Ltd. Jul 2020 Joined the Company; Executive Officer May 2021 Director, in charge of Administration Division (current)
1977-01-29
Tomomitsu MOTOHASHI
Director, CTO
Apr 2009 Joined NS Solutions Corporation (now Nippon Steel Solutions Corporation) Jul 2016 Joined Recruit Lifestyle Co., Ltd. (now Recruit Co., Ltd.) Jan 2017 Seconded to Recruit Communications Co., Ltd. (now Recruit Co., Ltd.) Nov 2017 Joined the Company Sep 2019 Director, CTO, in charge of System Development Division (current)
1983-08-14
Kuniaki KAGA
Director
Apr 1975 Joined Mitsubishi Kasei Corporation (now Mitsubishi Chemical Corporation) Jun 2006 Executive Officer, Head of Healthcare Strategy Office, Mitsubishi Chemical Holdings Corporation (now Mitsubishi Chemical Group Corporation) Jun 2010 Representative Director, Managing Executive Officer, Head of International Business Division (Assistant to the President; overall overseas management), Tanabe Mitsubishi Pharma Corporation (now Tanabe Pharma Corporation) Apr 2012 Representative Director, Senior Managing Executive Officer, Head of Research Division and Head of International Business Division (Assistant to the President; overall overseas management; in charge of Internal Control and Compliance Promotion Department), same company; Chief Compliance Officer Apr 2014 Representative Director, President, Life Science Institute, Inc.; Director, Tanabe Mitsubishi Pharma Corporation; Director, Earth Comfort Institute Inc. (now Mitsubishi Chemical Group Corporation) Feb 2015 Representative Director, President, Earth Comfort Institute Inc. (now Mitsubishi Chemical Group Corporation) Jun 2018 Outside Director, Sosei Group Corporation (now Nxera Pharma Co., Ltd.) Dec 2019 Advisor, Advisory Company Inc. Jan 2021 Outside Director, the Company (current)
1951-09-01
Mitsuya KAWARASAKI
Director (Full-time Audit and Supervisory Committee Member)
Apr 1986 Joined Sumitomo Life Insurance Company Jan 1999 Joined Sumitomo Life Investment Co., Ltd. (now Sumitomo Mitsui DS Asset Management Company, Limited) Apr 2005 Joined Sumitomo Mitsui Asset Management Company, Limited (now Sumitomo Mitsui DS Asset Management Company, Limited); Head of Insurance Asset Management Group No. 2 Apr 2008 Head of General Affairs and Human Resources Department, same company Apr 2012 Executive Officer, same company Jul 2016 Managing Executive Officer, same company Apr 2019 Managing Executive Officer, Sumitomo Mitsui DS Asset Management Company, Limited Jun 2022 Full-time Audit & Supervisory Board Member, same company Sep 2026 Outside Director (Full-time Audit and Supervisory Committee Member), the Company (current)
1963-01-25
Kenta NAGAO
Director (Audit and Supervisory Committee Member)
Oct 1986 Joined Chuo Accounting Office (audit corporation) Aug 1990 Registered as Certified Public Accountant Feb 1996 Opened Nagao Certified Public Accountant Office Jul 1997 Registered as Certified Tax Accountant Jun 2002 Outside Auditor, OBIC Co., Ltd. Sep 2003 Outside Auditor, Cyberstep, Inc. (now Cyberstep Holdings, Inc.) Dec 2004 Outside Auditor, Land Business Co., Ltd. Aug 2011 Representative Partner, Growing Tax Accountant Corporation (current) Dec 2019 Outside Auditor, Ascot Corporation (current) Sep 2020 Outside Auditor, the Company Sep 2024 Outside Director (Audit and Supervisory Committee Member), the Company (current)
1958-12-25
Makiko YAMAMOTO
Director (Audit and Supervisory Committee Member)
Jul 1995 Joined TMI Associates Oct 2000 Registered with Tokyo Bar Association Sep 2005 Joined Simmons & Simmons (London) Sep 2006 Returned to TMI Associates Feb 2012 Registered as Solicitor, Law Society of England and Wales Jun 2012 Joined Simmons & Simmons (London) Jan 2016 Partner, TMI Associates (current) Jun 2016 Outside Auditor, Starzen Co., Ltd. Jun 2018 Outside Director, Sigmaxis Inc. (now Sigmaxis Holdings Inc.) Jun 2019 Outside Director (Audit and Supervisory Committee Member), Musashi Seimitsu Industry Co., Ltd. (current) Feb 2020 Registered with Fukuoka Bar Association; Partner, TMI Partners Law Corporation (current) Mar 2020 Outside Director, ASICS Corporation Sep 2021 Outside Auditor, the Company Sep 2024 Outside Director (Audit and Supervisory Committee Member), the Company (current) Jul 2025 Solicitor, TMI Associates London LLP Oct 2025 Managing Partner, TMI Associates London LLP (current)
1971-05-29
Large Shareholding Reports
Sparx Asset Management Co., Ltd.
2026-09-02
5.16%→4.00%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-09-29
Annual Securities Report
Period: Jul 2025 – Jun 2026
EDINET
2026-09-02
Large Shareholding Report
TDnet
2026-08-07
Full-Year Earnings Flash
FY ending Jun 2026
TDnet
2026-05-08
Q3 Earnings Flash
FY ending Jun 2026
EDINET
2026-02-13
Semi-Annual Securities Report
Period: Jul 2025 – Jun 2026
TDnet
2025-11-07
Q1 Earnings Flash
FY ending Jun 2026
EDINET
2025-09-26
Annual Securities Report
Period: Jul 2024 – Jun 2025
TDnet
2025-05-09
Q3 Earnings Flash
FY ending Jun 2025
EDINET
2025-02-14
Semi-Annual Securities Report
Period: Jul 2024 – Jun 2025
TDnet
2024-11-08
Q1 Earnings Flash
FY ending Jun 2025
EDINET
2024-09-27
Annual Securities Report
Period: Jul 2023 – Jun 2024
EDINET
2024-05-10
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-09-29
Annual Securities Report
Period: Jul 2022 – Jun 2023
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-02-10
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-09-30
Annual Securities Report
EDINET
2022-08-26
Securities Registration Statement
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-02-10
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →